Cinaron

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cinaron

Cinaron is a pharmaceutical product, internationally recognized as containing the active ingredient Cinnarizine, primarily used to help alleviate symptoms associated with disturbances of the body's sense of balance and motion sickness. The medicine is a synthetic compound that is supplied in the form of a tablet for oral administration.


Quick Facts

Property Description
Active ingredient Cinnarizine
Form Tablet
Pharmacological class H₁-Receptor Antagonist and Calcium Channel Blocker
General purpose Stabilizing balance and easing motion-related discomfort
Origin Synthetic diphenylmethylpiperazine derivative

What Type of Medicine is Cinaron (Cinnarizine)?

Cinaron is classified as an antivertigo preparation (N07CA02). Its active component, Cinnarizine, belongs to a dual pharmacological class: it acts as a first-generation H₁-receptor antagonist (an antihistamine) and concurrently as a calcium channel blocker. This combination is structurally distinctive, being a derivative of diphenylmethylpiperazine.

Cinnarizine is recognized for its ability to control symptoms of vertigo by suppressing vestibular function. This action helps quiet down the overactive inner ear signals that cause spinning sensations. Cinaron's dual mechanism, addressing both neural signals and vascular tone, is a differentiating factor, contrasting it with simpler antihistamines used for similar applications.


Composition and General Purpose

The core component of Cinaron is the single active substance, Cinnarizine, typically presented for oral consumption as a simple, swallowable tablet. Cinnarizine is formulated with solid pharmaceutical excipients (inert ingredients) to create the stable dosage form.

The general purpose of Cinaron is to provide labyrinthine sedation and act as a peripheral vasorelaxant. Cinnarizine inhibits calcium influx in vascular smooth muscle cells. This indicates that the medicine helps improve blood flow by relaxing the walls of small vessels in the head. By combining these actions, the drug helps stabilize the body’s sense of equilibrium, offering relief in a typical scenario where the patient experiences the rotational sensation of vertigo.

Regulatory References

  1. Cinnarizine Inhibition of Calcium Influx (NIH/PMC)

What side effects are possible with Cinaron?

Possible Side Effects and Safety Information

The safety profile of Cinaron (Cinnarizine) is based on classifications defined in official government regulatory documents. Adverse reactions are grouped by frequency and the body system affected, ensuring a comprehensive view of possible outcomes.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by how often they are officially documented to occur:

Classification Examples of Documented Effects
Common (affecting 1 to 10 users in 100) Somnolence (drowsiness), Nausea, Weight increased
Uncommon (affecting 1 to 10 users in 1,000) Lethargy, Upper Abdominal Pain, Sweating, Fatigue

System-Organ-Class Safety Notes

The most frequently affected systems documented in the official labels are the Nervous System (somnolence, lethargy) and the Gastrointestinal System (nausea, abdominal pain). Effects on Metabolism and Nutrition (weight increase) and Skin (sweating) are also officially noted.


Serious and Population-Specific Safety Considerations

Regulatory documentation lists Extrapyramidal Symptoms (EPS), including Parkinsonism and Tremor, as a serious adverse reaction of 'not known' frequency, particularly associated with prolonged use. The risk of developing EPS is specifically increased in older adults. For this reason, official labels recommend caution, as use may aggravate pre-existing Parkinson's disease.

Furthermore, the official prescribing information includes safety constraints, such as the requirement for caution when Cinnarizine is used with other Central Nervous System (CNS) depressants, due to the potential for increased sedation. The label also requires avoidance in individuals with Porphyria.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Cinaron (Cinnarizine) defines overdosage by a specific profile of symptoms and a clear mandate for emergency action. The most commonly reported clinical effects include alterations in consciousness, ranging from somnolence and stupor to a state of coma, often accompanied by vomiting, extrapyramidal symptoms, and hypotonia. These clinical manifestations are mainly attributed to the drug's anticholinergic activity, as noted in the prescribing information.

Urgent medical attention is required for any suspected overdosage due to the potential for severe and life-threatening consequences. Regulatory sources specify that overdosage may lead to seizures (convulsions), and, in the most severe cases, cardiorespiratory collapse and death have been reported. A critical note is the heightened risk for young children and infants, who are particularly susceptible to severe neurological effects and must be observed in a health care facility.

No specific antidote is known for Cinnarizine overdosage. Therefore, treatment is strictly limited to symptomatic and supportive care. Regulatory texts advise contacting a poison control centre and may include the use of procedures like gastric lavage or the administration of activated charcoal to reduce absorption. This approach emphasizes that all management is procedural and focused on managing the documented manifestations.

Therapeutic Uses of Cinaron

Quick Facts: Cinaron

  • Balance Disorders: Intended to help manage symptoms related to conditions like Meniere's syndrome, including feelings of spinning or dizziness (vertigo) and associated nausea.
  • Motion Sickness: Used to help prevent or manage the symptoms of motion sickness, such as nausea and vomiting during travel.
  • Circulatory Support: May assist in the management of symptoms associated with certain cerebral and peripheral circulatory disorders.

Therapeutic Overview

Cinaron (Cinnarizine) is an option utilized primarily for its potential benefits in the management of vestibular and circulatory concerns. It is intended to help manage symptoms associated with balance disorders, notably Meniere’s syndrome, where it may assist in reducing the occurrence of dizziness, spinning sensations (vertigo), and giddiness. The medication is also used for the prophylaxis and management of motion sickness, helping to address related nausea and vomiting.

Furthermore, Cinaron may be indicated for the supportive management of symptoms associated with specific peripheral and cerebral vascular disorders, such as those that may contribute to poor circulation. This includes conditions that involve symptoms like ear buzzing (tinnitus) and vascular headaches, or issues related to intermittent claudication.

Eligibility and Restrictions for Use

Eligibility Scope

The following rules define who is allowed to use Cinaron (Cinnarizine) and who is excluded, as stated in official government regulatory documents.

Classification Populations Status/Restriction
Allowed Use Adults and adolescents mathbf12 years and over Generally permitted.
Children mathbf5 to 11 years Use established, typically for motion sickness.
Contraindicated Known hypersensitivity to Cinnarizine or excipients Must NOT use.
Patients with Porphyria Must NOT use.
Severe Renal or Hepatic impairment Not Recommended (often for combination products).
Conditional Use Patients with Parkinson’s disease Only if benefits outweigh the risk of aggravation.
Elderly patients Use with particular caution due to risk of extrapyramidal symptoms.

Physiological Status Limitations

Classification Status
Pregnancy Not Recommended; safety has not been established.
Lactation Not Recommended; lack of data on excretion in breast milk.

Connection to the overall eligibility profile: Regulatory documents define eligibility by classifying populations who are absolutely prohibited from use (contraindications) and those who require restrictions or caution. These constraints are primarily based on age thresholds, the presence of specific comorbidities (like Parkinson's disease), pre-existing organ impairment (hepatic or renal), and a lack of established safety data for physiological states such as pregnancy and lactation.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official interaction profile for Cinaron (Cinnarizine) focuses on the potential for pharmacodynamic potentiation and interference with diagnostic procedures, as documented in regulatory prescribing information. The medicine's H1-receptor antagonist activity is central to these documented interactions.


Documented Interaction Patterns

Category Official Regulatory Statement
Pharmacodynamic Interactions Co-administration with Central Nervous System ( CNS) Depressants and Tricyclic Antidepressants may potentiate the sedative effects.
Substance Interactions Consumption of alcohol is documented to result in the potentiation of sedative effects and should therefore be avoided.
Diagnostic Interference Cinnarizine may prevent an otherwise positive reaction to dermal reactivity indicators (skin tests).
Timing-based Restriction Must be avoided within four days prior to the performance of diagnostic skin tests.
Administration Constraint Taking the medicine after meals may diminish the potential for gastric irritation.
Population Caution Cinaron should be used with care in patients with hepatic or renal insufficiency due to potential for altered clearance.

These statements define the product's regulatory interaction structure. The primary restriction is due to additive CNS effects with other sedating agents, requiring avoidance of alcohol and caution with co-administered depressants. The secondary restriction requires a four-day separation from dermal allergy testing procedures.

Mechanism of Action

Cinaron (cinnarizine) functions primarily as a selective voltage-gated L-type calcium channel inhibitor on vascular smooth muscle cells, particularly targeting peripheral and labyrinthine circulation.

This antagonistic interaction prevents the transmembrane influx of calcium ions (Ca^2+), which is essential for the activation of the calcium-calmodulin complex. Consequently, this disrupts the downstream cascade that leads to the phosphorylation of the myosin light chain, ultimately inhibiting the contraction of the smooth muscle fibers. The system-level consequence is vasodilation and a resultant increase in local tissue perfusion, including in the inner ear's microvasculature.

Furthermore, the compound acts as a competitive antagonist at both the Histamine H1 receptors and Dopamine D2 receptors in the central nervous system, particularly within the vestibular and extrapyramidal structures. The H1 antagonism produces a depressant effect on the central vestibular apparatus, modifying neural activity between the inner ear and the emetic center. The D2 receptor antagonism modulates dopaminergic signaling pathways in the striatum.

Dosage and Administration Information

How to Use Cinaron

Cinaron (Cinnarizine) is strictly an oral medication, typically supplied as a tablet (e.g., 15 mg or 25 mg) or capsule. Use is guided by the condition being addressed, with specific dosing and frequency patterns established for the active ingredient. A central instruction for administration is that Cinaron should preferably be taken after meals (post-prandially) to help mitigate potential gastric irritation.


Official Dosing and Frequency

The total daily dosage is typically divided into multiple administrations. The maximum recommended dosage for adults should not exceed 225 mg daily in certain regimens.

Indication Standard Adult Dose (Age 12 years) Frequency Pattern
Vestibular/Balance Disorders 25 mg to 30 mg Three times daily (TID)
Motion Sickness Prevention 25 mg to 30 mg Taken 2 hours before travel, then repeated every 6 to 8 hours

Administration Rules for Specific Populations

Pediatric Dosing: Cinaron is approved for use in children aged 5 years and over. The dosage administered to children aged 5 to 11 years is generally half the adult dose, such as 15 mg three times daily for balance disorders.

Missed Dose: If a dose is forgotten, it is essential to ensure a minimum interval of 8 hours between any subsequent doses and to avoid taking a double dose to compensate. For chronic conditions, treatment may be required for several months, whereas for motion sickness, use is restricted to the duration of the journey.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cinaron (Cinnarizine)

Evidence for Use in Vestibular and Balance Disorders

Cinaron was studied for its role in conditions characterized by fluctuating or episodic manifestations, such as various forms of vertigo, spinning, and dizziness linked to disturbances in the inner ear’s sense of balance. The research base includes Randomized Controlled Trials (RCTs) and systematic reviews that explored outcomes by comparing the regimen against placebo or other active-control substances. These trials generally focused on adults who were experiencing periods of heightened symptom activity.

Researchers examined patient-reported outcomes describing perceived discomfort, monitoring changes in symptom intensity or variability and related outcomes related to physical discomfort, such as nausea. Findings describe patterns observed in the studies where the active substance was associated with measured differences in short-term symptom scores relative to control groups over defined time intervals, typically up to three months.

What is Still Uncertain About Cinaron Research

The evidence quality varies across studies. Many key trials for vertigo symptoms rely on data from a fixed-dose combination product rather than the monotherapy, meaning the specific contribution of Cinnarizine alone is not clearly delineated from the fixed-dose combination data. The follow-up durations were limited across most pivotal trials, which leaves the long-term effects on symptom management not well-characterized.

Research for the prevention of motion sickness primarily involved acute, single-dose RCTs in healthy adults. These studies monitored the measured effect of the regimen on episodic or acute changes like vomiting and psychomotor performance. For supportive circulatory symptom management, the evidence base consists mainly of older clinical trials, and the certainty remains low for these specific uses according to modern standards. Data for certain groups remain insufficient, particularly for children, where subgroup findings are uncertain when compared to the evidence base for adults.

Key Studies & References

  1. Cinnarizine in the prophylaxis of car sickness in children (Open study)

Frequently Asked Questions (FAQ)

Common questions about Cinaron (FAQ)


Q: Is Cinaron considered a common treatment for [Specific Condition from official uses, e.g., 'Vertigo']?

Official documents classify Cinnarizine, the active component in Cinaron, as a medicine approved for symptoms linked to balance disorders, including vertigo. The medicine is approved for these indications and is widely available as a generic drug in many regions.


Q: Are there any common over-the-counter medicines or supplements that interact with Cinaron?

Regulatory information indicates that Cinaron's Central Nervous System (CNS) depressant effect may be potentiated (increased) by other medicines that cause drowsiness. This warning applies to various over-the-counter remedies, such as certain antihistamines or sleep aids. The product label contains a detailed interaction profile for reference.


Q: Are there official warnings about Cinaron and driving or operating machinery?

Yes, official regulatory labels carry warnings regarding driving and operating heavy machinery. This caution is due to the potential for somnolence (drowsiness), which is commonly reported when treatment is initiated. Official guidance recommends awareness of one's normal reactions before engaging in these activities.


Q: Does Cinaron affect sleep or cause insomnia?

Cinaron is officially documented to commonly cause somnolence (drowsiness) and lethargy, which are states of sleepiness and lack of energy. While these effects impact the sleep-wake cycle, insomnia (difficulty sleeping) is generally not listed as a frequent adverse reaction on regulatory labels.


Q: Is it normal to feel [A non-serious, common side effect, e.g., 'a little dizzy'] when first starting Cinaron?

The most common side effect officially reported when starting Cinaron is somnolence (drowsiness). The complete list of documented adverse reactions is available in the patient information leaflet.


Q: How long does the effect of one dose of Cinaron typically last?

According to official pharmacokinetic information, the active component Cinnarizine typically reaches its peak concentration in the blood within 1 to 4 hours after a dose. The drug's elimination half-life, which reflects how quickly it is cleared from the body, generally ranges from 3 to 6 hours.


Q: Are there any dietary restrictions mentioned in the patient leaflet for Cinaron?

Official regulatory information requires the avoidance of alcohol consumption because it can potentiate the sedative effects of the medicine. Although the medicine is recommended to be taken after meals to reduce stomach irritation, no other specific formal food restrictions are noted in the regulatory documents.


Q: What is the risk of a severe allergic reaction to Cinaron?

A known hypersensitivity (severe allergic reaction) to Cinnarizine is listed as a contraindication, meaning the use of this medicine is prohibited for individuals with a history of this reaction. Regulatory safety plans list hypersensitivity as an important identified risk, confirming the potential for this type of reaction.


Q: Do food or dairy products affect the absorption of Cinaron?

Cinaron is recommended to be taken after meals to help prevent gastric irritation. While some medications experience changes in absorption or effectiveness when taken with food, the official recommendation for Cinaron is primarily related to improving digestive comfort.


Q: How does the medicine Cinaron actually get cleared from the body?

Official regulatory documents explain that Cinnarizine is extensively metabolized, or broken down, primarily in the liver by the CYP2D6 enzyme system. It is then eliminated from the body largely in the faeces (about two-thirds) and in the urine (about one-third) predominantly as metabolites (broken-down substances).


Q: Are there specific times of day Cinaron is usually recommended to be taken?

For chronic conditions, the total daily dosage is typically divided into two or three administrations throughout the day, in line with the typical requirement to divide the dose over the day. Official documents also recommend taking the dose after meals to help reduce gastric irritation.


Q: How long after starting Cinaron might I notice any effects?

After taking a dose of Cinaron by mouth, the active ingredient Cinnarizine typically reaches its maximum concentration in the blood within 1 to 4 hours. This peak concentration timeframe is when the drug's action begins to be observed.


Q: What are the differences between how Cinaron is approved in the US versus Europe?

Regulatory information indicates that Cinnarizine is approved and widely available in many countries, particularly throughout Europe, often under various brand names. Cinaron's active component is not currently approved for commercial use in the United States or Canada.


Q: Does official research describe Cinaron as 'well-tolerated'?

Clinical studies and reviews based on collected patient data frequently describe Cinnarizine as generally well-tolerated. This assessment is often linked to the observation that side effects associated with the medicine are typically mild and manageable.


Q: Are there any official reports of Cinaron causing changes in mood?

Official adverse reaction lists do not commonly classify changes in mood as frequent side effects. Cinnarizine acts on dopamine pathways, but changes in mood are not classified as common or uncommon adverse reactions in official documentation.


Q: Are there specific symptoms that mean I should stop taking Cinaron immediately?

Cinaron is strictly contraindicated in patients with known hypersensitivity (severe allergic reaction). Therefore, any signs of a serious allergic event, such as difficulty breathing or swelling of the face, tongue, or throat, require urgent medical review.


Q: Why is Cinaron sometimes associated with treating tinnitus?

Official regulatory documents explicitly include tinnitus as one of the symptoms Cinaron is approved to treat. It is indicated for maintenance therapy for symptoms associated with labyrinthine (inner ear) disorders.


Q: What does the patient leaflet say about taking Cinaron before surgery?

Due to the drug's Central Nervous System (CNS) depressant effects, which may be additive with anesthesia and other medicines used during surgery, medical guidance suggests careful review. The continued use of Cinaron prior to any operation is subject to review and management by the surgical care team.


Q: Is there a generic version of Cinaron available?

Yes, Cinaron is a brand name for the active ingredient Cinnarizine. The medicine is widely available under its generic name, Cinnarizine, in many countries.


Q: What is the chemical difference between Cinaron and its primary metabolite (if applicable)?

Regulatory information and clinical literature describe that Cinnarizine is broken down into several compounds called metabolites, primarily in the liver. These metabolites (such as C-1, C-2, C-3, C-4) differ chemically from Cinnarizine through specific processes like oxidation and N-desalkylation.


Q: Does Cinaron have any known effects on blood pressure?

Cinaron's mechanism of action involves acting as a calcium channel blocker, which results in vasodilation (widening of blood vessels). While regulatory labels do not list blood pressure changes as a common side effect at therapeutic doses, hypotension (low blood pressure) is a documented symptom in cases of overdose.


Q: Is Cinaron available without a prescription in some countries?

In certain regions, such as the United Kingdom, Cinaron (Cinnarizine) is available for purchase without a prescription. The regulatory status of the medicine can differ across various countries.

How should Cinaron be stored and disposed of?

How to Store and Dispose of Cinaron?

The following instructions reflect the official storage and disposal requirements for Cinaron based on regulatory labeling:

Storage Requirements

Condition Regulatory Statement
Temperature Store below 30°C.
Protection Protect from light; keep in the original packaging.
Safety Keep this medicine out of the sight and reach of children.
Stability Do not use this medicine after the expiry date stated on the carton.

Disposal Instructions

Regulatory documents mandate specific rules for disposing of unused or expired medicine to protect the environment. Do not throw away any medicines via wastewater or household waste. Instead, consult your pharmacist on the proper method for disposal, ensuring compliance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cinaron found in:

A-Z Index: